Michael Schmidt
Stock Analyst
(3.80)
# 2,333
Out of 4,648 analysts
71
Total ratings
57.14%
Success rate
7.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Maintains: Buy | $32 → $33 | $34.46 | -4.22% | 7 | Oct 30, 2024 | |
| IMCR Immunocore Holdings | Downgrades: Neutral | n/a | $31.43 | - | 3 | Oct 7, 2024 | |
| VSTM Verastem | Initiates: Buy | $13 | $3.91 | +232.91% | 1 | Sep 30, 2024 | |
| INCY Incyte | Maintains: Buy | $86 → $92 | $75.82 | +21.34% | 4 | Sep 16, 2024 | |
| NBTX Nanobiotix | Initiates: Buy | $12 | $4.50 | +166.96% | 1 | Aug 28, 2024 | |
| BOLT Bolt Biotherapeutics | Downgrades: Neutral | n/a | $0.67 | - | 2 | May 15, 2024 | |
| IMNM Immunome | Initiates: Buy | $35 | $12.79 | +173.65% | 1 | Apr 15, 2024 | |
| ADCT ADC Therapeutics | Reiterates: Buy | n/a | $3.08 | - | 2 | Apr 5, 2024 | |
| IMRX Immuneering | Downgrades: Neutral | n/a | $1.87 | - | 2 | Mar 14, 2024 | |
| MRSN Mersana Therapeutics | Upgrades: Buy | $7 | $1.86 | +276.34% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $345 | $208.41 | +65.54% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.96 | - | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $34 | $21.68 | +56.83% | 4 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $42 | $19.08 | +120.18% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 | $1.28 | +1,468.63% | 3 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $82 | $92.23 | -11.09% | 1 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 | $9.47 | +58.48% | 3 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $27.01 | - | 1 | Jan 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $5 | $0.81 | +517.59% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $28 | $3.82 | +633.94% | 2 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $22.79 | - | 2 | Jan 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $2.85 | +777.19% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $8.99 | +233.70% | 1 | Jul 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.80 | - | 2 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $56.50 | -11.50% | 1 | Mar 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.46 | - | 4 | Mar 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $80 | $44.71 | +78.95% | 5 | Feb 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.59 | - | 6 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $4 → $5.5 | $3.88 | +41.75% | 2 | Nov 7, 2017 |
Exelixis
Oct 30, 2024
Maintains: Buy
Price Target: $32 → $33
Current: $34.46
Upside: -4.22%
Immunocore Holdings
Oct 7, 2024
Downgrades: Neutral
Price Target: n/a
Current: $31.43
Upside: -
Verastem
Sep 30, 2024
Initiates: Buy
Price Target: $13
Current: $3.91
Upside: +232.91%
Incyte
Sep 16, 2024
Maintains: Buy
Price Target: $86 → $92
Current: $75.82
Upside: +21.34%
Nanobiotix
Aug 28, 2024
Initiates: Buy
Price Target: $12
Current: $4.50
Upside: +166.96%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.67
Upside: -
Immunome
Apr 15, 2024
Initiates: Buy
Price Target: $35
Current: $12.79
Upside: +173.65%
ADC Therapeutics
Apr 5, 2024
Reiterates: Buy
Price Target: n/a
Current: $3.08
Upside: -
Immuneering
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.87
Upside: -
Mersana Therapeutics
Feb 29, 2024
Upgrades: Buy
Price Target: $7
Current: $1.86
Upside: +276.34%
Feb 27, 2024
Maintains: Buy
Price Target: $350 → $345
Current: $208.41
Upside: +65.54%
Jan 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.96
Upside: -
Nov 8, 2023
Maintains: Buy
Price Target: $40 → $34
Current: $21.68
Upside: +56.83%
Jul 25, 2023
Maintains: Buy
Price Target: $40 → $42
Current: $19.08
Upside: +120.18%
Jun 27, 2023
Downgrades: Neutral
Price Target: $20
Current: $1.28
Upside: +1,468.63%
May 23, 2023
Maintains: Buy
Price Target: $78 → $82
Current: $92.23
Upside: -11.09%
Mar 21, 2023
Downgrades: Neutral
Price Target: $15
Current: $9.47
Upside: +58.48%
Jan 12, 2023
Downgrades: Neutral
Price Target: n/a
Current: $27.01
Upside: -
Jan 3, 2023
Upgrades: Buy
Price Target: $5
Current: $0.81
Upside: +517.59%
Nov 11, 2022
Maintains: Buy
Price Target: $55 → $28
Current: $3.82
Upside: +633.94%
Jan 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $22.79
Upside: -
Aug 10, 2021
Initiates: Buy
Price Target: $25
Current: $2.85
Upside: +777.19%
Jul 19, 2021
Initiates: Buy
Price Target: $30
Current: $8.99
Upside: +233.70%
Apr 28, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.80
Upside: -
Mar 9, 2020
Initiates: Buy
Price Target: $50
Current: $56.50
Upside: -11.50%
Mar 5, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $0.46
Upside: -
Feb 15, 2019
Upgrades: Outperform
Price Target: $80
Current: $44.71
Upside: +78.95%
Jan 17, 2019
Initiates: Outperform
Price Target: n/a
Current: $7.59
Upside: -
Nov 7, 2017
Maintains: Market Perform
Price Target: $4 → $5.5
Current: $3.88
Upside: +41.75%